CFT8634 discontinue
C4 Therapeutics Halts Cancer Project Post Phase 1/2 Trial Setback
Anika Sharma
C4 Therapeutics has made a strategic decision to discontinue the development of CFT8634, an oral BRD9 degrader, following a phase ...
C4 Therapeutics has made a strategic decision to discontinue the development of CFT8634, an oral BRD9 degrader, following a phase ...